title: Current role of metaiodobenzylguanidine in the diagnosis of pheochromocytoma and medullary thyroid cancer.
abstract: Despite early reports of excellent diagnostic characteristics of [(131)I]/[(123)I]-metaiodobenzylguanidine (MIBG) in the evaluation of pheochromocytomas/paragangliomas (PHEOs/PGLs) or medullary thyroid cancer as experience with it was accumulated, the sensitivity dropped. Nevertheless, this modality is still useful in the diagnostic work-up of PHEOs/PGLs because it is widely available, and in case of positive scans it might indicate patients who are potential candidates for [(131)I]MIBG therapy.
authors.affiliation: Department of Endocrinology, E. Venizelou Hospital, Athens, Greece.
authors.forename: Ioannis
authors.initials: I
authors.lastname: Ilias
authors.forename: Chaitanya
authors.initials: C
authors.lastname: Divgi
authors.forename: Karel
authors.initials: K
authors.lastname: Pacak
mesh_terms: D019797:3-Iodobenzylguanidine / Q000378:metabolism; D000310:Adrenal Gland Neoplasms / Q000175:diagnosis* / Q000378:metabolism; D000818:Animals; D001692:Biological Transport; D018278:Carcinoma, Neuroendocrine; D006801:Humans; D010673:Pheochromocytoma / Q000175:diagnosis* / Q000378:metabolism; D013964:Thyroid Neoplasms / Q000175:diagnosis* / Q000378:metabolism
chemical_list: D019797:3-Iodobenzylguanidine